Global Licensing Potential Promontory's exclusive global license to phosphaplatins, plus Greater China rights via SciClone, creates a multi-territory out-licensing and co-development path; target big pharma for regional commercialization and late-stage collaboration.

Late Stage Partnership PT-112 features two FDA IND approvals and Phase 2 data from an NCI collaboration; this strengthens a case for partnered late-stage development, with milestone- and royalty-ready structures.

European Growth Access France expansion and Paris-Saclay Cancer Center membership signal a commitment to Europe; pursue partnerships for joint trials, local funding, and potential manufacturing or distribution deals in the EU.

Immunogenic Advantage Immunogenic small molecule approach differentiates Promontory's oncology portfolio; seek partnerships focusing on combination strategies with checkpoint inhibitors or other immunotherapies.

Validation Powered BD NCI collaboration adds credible data and visibility; use as leverage to attract licensing partners and co-funding opportunities, plus grant support or government programs.